iShares Biotechnology ETF : IBB

Price Target

›

IBB

Stock Data

$167.27

$1.42 (0.84%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

All IBB Articles

63 Articles

David Beren | Apr 23, 2026 at 1:22 PM EDT

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here’s How to Position Now

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and renewed merger…

David Beren | Apr 7, 2026 at 10:20 AM EDT

XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early…

John Seetoo | Mar 31, 2026 at 10:50 AM EDT

Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead

The bulk of coverage towards the top gaining stock sectors over the past year has focused understandably on technology, which…

Austin Smith | Mar 11, 2026 at 12:37 PM EDT

Josh Brown: Biotech growth stocks immune to disruption risk

Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap biotech:…

Austin Smith | Jan 16, 2026 at 8:06 AM EST

Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull…

Joey Frenette | Dec 26, 2025 at 11:52 AM EST

2 Top Growth Themes Beyond AI and How to Invest in Them

The AI trade has been wobbling quite a bit in recent weeks, to say the least. And while the popping…

Joey Frenette | Dec 14, 2025 at 10:58 AM EST

2 Brilliant Biotech ETFs to Watch in 2026

As the AI trade gets overheated and calls for some sort of bursting of the AI bubble grow louder, it…

Joey Frenette | Jan 23, 2025 at 12:01 PM EST

I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the Game

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After…

Chris Lange | Sep 10, 2020 at 7:55 AM EDT

5 Very Undervalued Large Cap Biotech Stocks That Could Explode in 2021

Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come…

Chris Lange | Aug 5, 2020 at 10:07 AM EDT

5 Large Biotech and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-19

24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense,…

Chris Lange | Jul 7, 2020 at 8:55 AM EDT

5 Speculative COVID-19 Stocks That Could Still Surge

24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a…

Chris Lange | Jul 3, 2020 at 7:33 AM EDT

5 FDA COVID-19 Decisions in July Could Make or Break Stocks

Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July…

Chris Lange | Jun 15, 2020 at 1:10 PM EDT

Canaccord Genuity’s Top Biopharma Catalysts for the Rest of 2020

Canaccord Genuity recently released a report detailing some of the biggest biotech catalysts coming out over these next six months.

Chris Lange | Jan 3, 2020 at 11:15 AM EST

The Top Biotech ETFs to Watch in 2020

On a company by company basis, investing in biotechs is somewhat tricky. However, there is an investment strategy that makes…

Chris Lange | Jun 18, 2019 at 11:57 AM EDT

Tuesday’s Top BioPharma Movers Deviating from the Market

24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each…

1 2 3 … 5

iShares Biotechnology ETF : IBB

IBB

$167.27

All IBB Articles

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here’s How to Position Now

XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026

Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead

Josh Brown: Biotech growth stocks immune to disruption risk

Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026

2 Top Growth Themes Beyond AI and How to Invest in Them

2 Brilliant Biotech ETFs to Watch in 2026

I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the Game

5 Very Undervalued Large Cap Biotech Stocks That Could Explode in 2021

5 Large Biotech and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-19

5 Speculative COVID-19 Stocks That Could Still Surge

5 FDA COVID-19 Decisions in July Could Make or Break Stocks

Canaccord Genuity’s Top Biopharma Catalysts for the Rest of 2020

The Top Biotech ETFs to Watch in 2020

Tuesday’s Top BioPharma Movers Deviating from the Market

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

iShares Biotechnology ETF : IBB

IBB

$167.27

All IBB Articles

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here’s How to Position Now

XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026

Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead

Josh Brown: Biotech growth stocks immune to disruption risk

Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026

2 Top Growth Themes Beyond AI and How to Invest in Them

2 Brilliant Biotech ETFs to Watch in 2026

I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the Game

5 Very Undervalued Large Cap Biotech Stocks That Could Explode in 2021

5 Large Biotech and Pharma Stocks Are Dirt Cheap, and Not Because of COVID-19

5 Speculative COVID-19 Stocks That Could Still Surge

5 FDA COVID-19 Decisions in July Could Make or Break Stocks

Canaccord Genuity’s Top Biopharma Catalysts for the Rest of 2020

The Top Biotech ETFs to Watch in 2020

Tuesday’s Top BioPharma Movers Deviating from the Market

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

Featured Reads

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not